

**CIN-L24232MP1983PLC002231**

BSE Code: 523144

14<sup>th</sup> July, 2018**Statement relating to Investors Complaints as per Regulation 13(3) of SEBI  
(LODR) Regulations, 2015 for the quarter ended 30<sup>th</sup> June, 2018.**

With reference to Sub Regulation (3) of Regulation 13 of SEBI (LODR) Regulations 2015, we hereby submit the Statement for the Investors Complaints received for the quarter ended 30<sup>th</sup> June, 2018 as under:

S.No.	Particulars	Comments
1	No. of complaints pending at the beginning of the quarter	0
2	No. of Complaints received during the quarter	1
3	No. of complaints disposed of during the quarter	1
4	No. of complaints remained unresolved at the end of the quarter	0


It may please be noted that the aforesaid report is based on the information provided by the Registrar and Share Transfer Agent as well as the complaints directly received by the Company and/or forwarded by the SEBI or BSE.

*Further with reference to the SEBI Circular LIST/COMP/26/2017-2018 dated 27<sup>th</sup> March, 2018, Investor Complaint Details (Regulation 13 (3)) has been filled in the Listing Centre website using the web form.*

Thanking you,  
Yours faithfully

**AUTHORIZED SIGNATORY**

FOR AND ON BEHALF OF  
MEDICAPS LIMITED

**Indore Office :****201, Pushpratna Paradise, 9/5, New Palasia, Indore 452 001 (INDIA)  
Telefax No. : +91-731-4046321, 4041435, 4028148**